Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Buy
62
DERM Quote, Financials, Valuation and Earnings
Last price:
$7.31
Seasonality move
:
16.99%
Day range:
$7.28 - $7.73
52-week range:
$3.20 - $7.84
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.71x
P/B ratio:
8.60x
Volume:
84.1K
Avg. volume:
95.4K
1-year change:
113.43%
Market cap:
$172.6M
Revenue:
$56.1M
EPS (TTM):
-$0.74
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DERM
Journey Medical
|
$12.1M | -- | -7.49% | -- | $9.88 |
|
CATX
Perspective Therapeutics
|
$143.9K | -$0.27 | -- | -35.77% | $14.39 |
|
FBIO
Fortress Biotech
|
$11.6M | -$0.44 | 5.94% | -96.07% | $15.33 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DERM
Journey Medical
|
$7.47 | $9.88 | $172.6M | -- | $0.00 | 0% | 2.71x |
|
CATX
Perspective Therapeutics
|
$2.39 | $14.39 | $177M | -- | $0.00 | 0% | 15.47x |
|
FBIO
Fortress Biotech
|
$1.64 | $15.33 | $48.5M | -- | $0.00 | 0% | 0.46x |
|
NBY
NovaBay Pharmaceuticals
|
$0.58 | $0.85 | $3.4M | -- | $0.00 | 0% | 0.16x |
|
PTN
Palatin Technologies
|
$0.21 | -- | $5.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.42 | $6.00 | $4M | -- | $0.00 | 0% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DERM
Journey Medical
|
55.35% | 1.457 | 30.46% | 0.87x |
|
CATX
Perspective Therapeutics
|
-- | -2.375 | -- | -- |
|
FBIO
Fortress Biotech
|
71.75% | 0.739 | 900.37% | 0.99x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.451 | 1.51% | 0.75x |
|
PTN
Palatin Technologies
|
-- | 0.220 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -1.635 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DERM
Journey Medical
|
$11.4M | -$2.3M | -43.33% | -97.05% | 17.72% | $2.2M |
|
CATX
Perspective Therapeutics
|
-- | -$20.9M | -- | -- | -- | -$41.2M |
|
FBIO
Fortress Biotech
|
$9.3M | -$22.1M | -94.06% | -- | -166.72% | -$20.1M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
Journey Medical vs. Competitors
-
Which has Higher Returns DERM or CATX?
Perspective Therapeutics has a net margin of 11.17% compared to Journey Medical's net margin of --. Journey Medical's return on equity of -97.05% beat Perspective Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical83.58% $0.08 $44.9M CATXPerspective Therapeutics-- -$0.61 -- -
What do Analysts Say About DERM or CATX?
Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 32.2%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 502.21%. Given that Perspective Therapeutics has higher upside potential than Journey Medical, analysts believe Perspective Therapeutics is more attractive than Journey Medical.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 CATXPerspective Therapeutics10 1 0 -
Is DERM or CATX More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.
-
Which is a Better Dividend Stock DERM or CATX?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or CATX?
Journey Medical quarterly revenues are $13.6M, which are larger than Perspective Therapeutics quarterly revenues of --. Journey Medical's net income of $1.5M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Journey Medical's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.71x versus 15.47x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical2.71x -- $13.6M $1.5M CATXPerspective Therapeutics15.47x -- -- -$40.2M
-
Which has Higher Returns DERM or FBIO?
Fortress Biotech has a net margin of 11.17% compared to Journey Medical's net margin of -87.96%. Journey Medical's return on equity of -97.05% beat Fortress Biotech's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical83.58% $0.08 $44.9M FBIOFortress Biotech63.87% -$0.76 $41M -
What do Analysts Say About DERM or FBIO?
Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 32.2%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 834.96%. Given that Fortress Biotech has higher upside potential than Journey Medical, analysts believe Fortress Biotech is more attractive than Journey Medical.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 FBIOFortress Biotech1 0 0 -
Is DERM or FBIO More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.825, suggesting its more volatile than the S&P 500 by 82.547%.
-
Which is a Better Dividend Stock DERM or FBIO?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or FBIO?
Journey Medical quarterly revenues are $13.6M, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Journey Medical's net income of $1.5M is higher than Fortress Biotech's net income of -$12.9M. Notably, Journey Medical's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.71x versus 0.46x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical2.71x -- $13.6M $1.5M FBIOFortress Biotech0.46x -- $14.6M -$12.9M
-
Which has Higher Returns DERM or NBY?
NovaBay Pharmaceuticals has a net margin of 11.17% compared to Journey Medical's net margin of -49.65%. Journey Medical's return on equity of -97.05% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical83.58% $0.08 $44.9M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About DERM or NBY?
Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 32.2%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that NovaBay Pharmaceuticals has higher upside potential than Journey Medical, analysts believe NovaBay Pharmaceuticals is more attractive than Journey Medical.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is DERM or NBY More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.
-
Which is a Better Dividend Stock DERM or NBY?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or NBY?
Journey Medical quarterly revenues are $13.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Journey Medical's net income of $1.5M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Journey Medical's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.71x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical2.71x -- $13.6M $1.5M NBYNovaBay Pharmaceuticals0.16x -- $2.4M -$1.2M
-
Which has Higher Returns DERM or PTN?
Palatin Technologies has a net margin of 11.17% compared to Journey Medical's net margin of --. Journey Medical's return on equity of -97.05% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical83.58% $0.08 $44.9M PTNPalatin Technologies-- -- -- -
What do Analysts Say About DERM or PTN?
Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 32.2%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3281.64%. Given that Palatin Technologies has higher upside potential than Journey Medical, analysts believe Palatin Technologies is more attractive than Journey Medical.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 PTNPalatin Technologies0 0 0 -
Is DERM or PTN More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.
-
Which is a Better Dividend Stock DERM or PTN?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or PTN?
Journey Medical quarterly revenues are $13.6M, which are larger than Palatin Technologies quarterly revenues of --. Journey Medical's net income of $1.5M is higher than Palatin Technologies's net income of --. Notably, Journey Medical's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.71x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical2.71x -- $13.6M $1.5M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns DERM or TOVX?
Theriva Biologics has a net margin of 11.17% compared to Journey Medical's net margin of --. Journey Medical's return on equity of -97.05% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical83.58% $0.08 $44.9M TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About DERM or TOVX?
Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 32.2%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 322.27%. Given that Theriva Biologics has higher upside potential than Journey Medical, analysts believe Theriva Biologics is more attractive than Journey Medical.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 TOVXTheriva Biologics0 0 0 -
Is DERM or TOVX More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.
-
Which is a Better Dividend Stock DERM or TOVX?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or TOVX?
Journey Medical quarterly revenues are $13.6M, which are larger than Theriva Biologics quarterly revenues of --. Journey Medical's net income of $1.5M is higher than Theriva Biologics's net income of -$4.4M. Notably, Journey Medical's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.71x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical2.71x -- $13.6M $1.5M TOVXTheriva Biologics0.63x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Netflix a Must-own Stock?
The early months of 2025 have been very hard on…
Why Did Bill Ackman Buy Uber Stock?
In February, Pershing Square manager Bill Ackman revealed that his…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 26
Saia [SAIA] is down 30.77% over the past day.
Sell
48
APPF alert for Apr 26
AppFolio [APPF] is down 18.16% over the past day.
Sell
15
KNSL alert for Apr 26
Kinsale Capital Group [KNSL] is down 16.33% over the past day.
